0
November 15, 1971, Vol 218, No. 7 >
ARTICLE | November 15, 1971

Long-Term Treatment of Hyperlipidemic Patients With Clofibrate FREE

Donald Berkowitz, MD
[+] Author Affiliations

Reprint requests to 245 N Broad St, Philadelphia 19107 (Dr. Berkowitz).


JAMA. 1971;218(7):1002-1005. doi:10.1001/jama.1971.03190200034006
Text Size: A A A
Published online
Article
References

In 50 hyperlipidemic patients who responded to clofibrate during a three-month trial period, the medication was continued for six to eight years. Eight of the subjects had essential hypercholesterolemia. The remainder had elevations of both the cholesterol and triglyceride levels. Normalization of the serum cholesterol level occurred in each patient and was maintained throughout the entire treatment period. Each of the 42 subjects with hypertriglyceridemia had at least a 25% reduction in those levels; normal values resulted in 38. A reduction in the serum uric acid level and improvement in oral glucose tolerance was also produced in more than 65% of those in whom these were abnormal initially. No evidence of clinical toxic reactions was present in any case.

REFERENCES

1 +
Oliver MF:  Reduction of serum-lipid and uric acid levels by an orally active androsterone . Lancet 1:1321-1323, 1962;.
2 +
Hellman L, Zumoff B, Kessler G, et al:  Reduction of cholesterol and lipids in man by ethyl p-chlorophenoxyisobutyrate . Ann Intern Med 59:477-494, 1963;.
3 +
Berkowitz D:  Effects of chlorophenoxyisobutyrate with and without androsterone on the serum lipids, fat tolerance and uric acid . Metabolism 14:966-975, 1965;.
4 +
Best MM, Duncan CH:  Effects of clofibrate and dextrothyroxine, single and in combination on serum lipids . Arch Intern Med 118:97-102, 1966;.
5 +
Orgain ES, Bogdonoff MD, Cain C:  Clofibrate and androsterone effect on serum lipids . Arch Intern Med 119:80-85, 1967;.
6 +
Duncan GG, Elliott FA, Duncan TG, et al:  Some clinical potentials of chlorophenoxyisobutyrate (clofibrate) therapy (hyperlipidemiaangina pectoris-blood sludging-diabetic neuropathy) . Metabolism 17:457-473, 1968;.
7 +
Jepson EM, Fahmy MFI, Torrens PE, et al:  Treatment of essential hyperlipidemia . Lancet 2:1315-1319, 1969;.
8 +
Oliver MF:  The current status of ethyl chlorophenoxyisobutyrate (Atromid-S) , in Kritchevsky D, Paoletti R, Steinberg D (eds): Progress in Biochemical Pharmacology . Basel, Switzerland, S. Karger, 1967;, vol 2, pp 315-324.
9 +
Hunninghake DB, Tucker DR, Azarnoff DL:  Long-term effects of clofibrate (Atromid-S) on serum lipids in man . Circulation 39:675-683, 1969;.
10 +
Vester JW, Sunder JH, Aarons JH, et al:  Long-term monitoring during clofibrate therapy . Clin Pharmacol Ther 11:689-697, 1970;.
11 +
Abell LL, Levy BB, Brodie BB, et al:  A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity . J Biol Chem 195:357-366, 1952;.
12 +
Van Handel E, Zilversmit DB:  Micro-method for the direct determination of serum triglycerides . J Lab Clin Med 50:152-157, 1957;.
13 +
Fajans SS:  Diagnostic tests for diabetes mellitus , in Williams RH (ed): Diabetes . New York, Paul B Hoeber, Inc, 1960;, pp 389-422.
14 +
Langer T, Levy RI:  Acute muscular syndrome associated with administration of clofibrate . New Eng J Med 279:856-858, 1968;.
15 +
Fredrickson DS, Levy RI, Lees RS:  Fat transport in lipoproteins. An integrated approach to mechanisms and disorders . New Eng J Med 276:34-42, 94-103, 148-156, 215-225, 273-281, 1967;.
16 +
Cornfield J, Mitchell S:  Selected risk factors in coronary disease . Arch Environ Health 19:382-391, 1969;.
17 +
Morrison LM:  A nutritional program for the prolongation of life in coronary atherosclerosis . JAMA 159:1425-1428, 1955;.
18 +
Page IH, Brown HB:  Some observations on the National Diet-Heart Study . Circulation 37:313-315, 1968;.
19 +
Levy RI, Fredrickson DS:  Diagnosis and management of hyperlipoproteinemia . Amer J Cardiol 22:575-583, 1968;.
20 +
Harlan WR Jr:  A practical approach to lowering plasma lipids . GP 39:101-111, 1969;.
21 +
Bierenbaum ML, Fleischman AI, Green DP, et al:  The five-year experience of modified fat diets in younger men with coronary heart disease . Circulation 42:943-952, 1970;.
22 +
Cornfield J:  Joint dependence of risk of coronary heart disease on serum cholesterol and systolic blood pressure: A discriminant function analysis . Fed Proc 21 ( (suppl 11) ):58-61, 1962;.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Oliver MF:  Reduction of serum-lipid and uric acid levels by an orally active androsterone . Lancet 1:1321-1323, 1962;.
2 +
Hellman L, Zumoff B, Kessler G, et al:  Reduction of cholesterol and lipids in man by ethyl p-chlorophenoxyisobutyrate . Ann Intern Med 59:477-494, 1963;.
3 +
Berkowitz D:  Effects of chlorophenoxyisobutyrate with and without androsterone on the serum lipids, fat tolerance and uric acid . Metabolism 14:966-975, 1965;.
4 +
Best MM, Duncan CH:  Effects of clofibrate and dextrothyroxine, single and in combination on serum lipids . Arch Intern Med 118:97-102, 1966;.
5 +
Orgain ES, Bogdonoff MD, Cain C:  Clofibrate and androsterone effect on serum lipids . Arch Intern Med 119:80-85, 1967;.
6 +
Duncan GG, Elliott FA, Duncan TG, et al:  Some clinical potentials of chlorophenoxyisobutyrate (clofibrate) therapy (hyperlipidemiaangina pectoris-blood sludging-diabetic neuropathy) . Metabolism 17:457-473, 1968;.
7 +
Jepson EM, Fahmy MFI, Torrens PE, et al:  Treatment of essential hyperlipidemia . Lancet 2:1315-1319, 1969;.
8 +
Oliver MF:  The current status of ethyl chlorophenoxyisobutyrate (Atromid-S) , in Kritchevsky D, Paoletti R, Steinberg D (eds): Progress in Biochemical Pharmacology . Basel, Switzerland, S. Karger, 1967;, vol 2, pp 315-324.
9 +
Hunninghake DB, Tucker DR, Azarnoff DL:  Long-term effects of clofibrate (Atromid-S) on serum lipids in man . Circulation 39:675-683, 1969;.
10 +
Vester JW, Sunder JH, Aarons JH, et al:  Long-term monitoring during clofibrate therapy . Clin Pharmacol Ther 11:689-697, 1970;.
11 +
Abell LL, Levy BB, Brodie BB, et al:  A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity . J Biol Chem 195:357-366, 1952;.
12 +
Van Handel E, Zilversmit DB:  Micro-method for the direct determination of serum triglycerides . J Lab Clin Med 50:152-157, 1957;.
13 +
Fajans SS:  Diagnostic tests for diabetes mellitus , in Williams RH (ed): Diabetes . New York, Paul B Hoeber, Inc, 1960;, pp 389-422.
14 +
Langer T, Levy RI:  Acute muscular syndrome associated with administration of clofibrate . New Eng J Med 279:856-858, 1968;.
15 +
Fredrickson DS, Levy RI, Lees RS:  Fat transport in lipoproteins. An integrated approach to mechanisms and disorders . New Eng J Med 276:34-42, 94-103, 148-156, 215-225, 273-281, 1967;.
16 +
Cornfield J, Mitchell S:  Selected risk factors in coronary disease . Arch Environ Health 19:382-391, 1969;.
17 +
Morrison LM:  A nutritional program for the prolongation of life in coronary atherosclerosis . JAMA 159:1425-1428, 1955;.
18 +
Page IH, Brown HB:  Some observations on the National Diet-Heart Study . Circulation 37:313-315, 1968;.
19 +
Levy RI, Fredrickson DS:  Diagnosis and management of hyperlipoproteinemia . Amer J Cardiol 22:575-583, 1968;.
20 +
Harlan WR Jr:  A practical approach to lowering plasma lipids . GP 39:101-111, 1969;.
21 +
Bierenbaum ML, Fleischman AI, Green DP, et al:  The five-year experience of modified fat diets in younger men with coronary heart disease . Circulation 42:943-952, 1970;.
22 +
Cornfield J:  Joint dependence of risk of coronary heart disease on serum cholesterol and systolic blood pressure: A discriminant function analysis . Fed Proc 21 ( (suppl 11) ):58-61, 1962;.

Letters

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems